371 related articles for article (PubMed ID: 20963831)
1. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
3. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
6. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
7. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
McKeage K
Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
[TBL] [Abstract][Full Text] [Related]
9. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
10. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
[TBL] [Abstract][Full Text] [Related]
13. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
[TBL] [Abstract][Full Text] [Related]
14. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
16. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
[TBL] [Abstract][Full Text] [Related]
17. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Hamed K; Debonnett L
Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
19. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
20. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
